Frequency Therapeutics (FREQ), which is a biotechnology company that focuses on harnessing the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases, most recently reported its first-quarter results and provided top line data from its exploratory study. The top line data confirmed that FX-322 was delivered to the intended target within the cochlea with drug levels that could be directly measured, while it was also predicted to result in therapeutic activity. This can be seen as promising initial results from the company's exploratory study conducted in